Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK has announced the purchase of 555,000 of its own ordinary shares as part of its ongoing buyback program, executed through BNP Paribas SA. This transaction, which took place on October 24, 2025, is part of a broader strategy to manage the company’s capital structure and return value to shareholders. Following this purchase, GSK holds 253,747,344 shares in treasury, with a total of 4,061,673,442 shares in issue, excluding treasury shares. The buyback program reflects GSK’s commitment to enhancing shareholder value and maintaining a robust financial position.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. The technical analysis supports a bullish outlook, though caution is advised due to nearing overbought indicators. Valuation is reasonable, providing a balanced investment opportunity.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a global healthcare company that operates in the pharmaceutical industry, focusing on the development and production of vaccines, medicines, and consumer healthcare products. The company is committed to improving the quality of human life by enabling people to do more, feel better, and live longer.
Average Trading Volume: 8,031,547
Technical Sentiment Signal: Buy
Current Market Cap: £65.11B
For an in-depth examination of GSK stock, go to TipRanks’ Overview page.